Male Hypoactive Sexual Desire Disorder (MHSDD): Symptoms, Causes, Diagnosis, and Treatment

Male Hypoactive Sexual Desire Disorder (MHSDD) is a sexual dysfunction characterized by a persistent or recurrent deficiency or absence of sexual or erotic thoughts, fantasies, and desire for sexual activity. According to the DSM-5-TR, this condition is specifically categorized as a male sexual dysfunction, distinct from its female counterpart (Female Sexual Interest/Arousal Disorder), reflecting important differences in how low desire manifests and is experienced across genders.

It is important to understand that sexual desire naturally fluctuates throughout a man's life. Temporary decreases in libido related to stress, fatigue, relationship conflict, or life transitions are normal and do not constitute a clinical disorder. MHSDD is diagnosed only when the reduced desire is persistent (typically lasting at least approximately six months), causes clinically significant distress to the individual, and is not better explained by another mental disorder, a medical condition, substance use, or severe relationship distress.

The DSM-5-TR requires clinicians to specify whether the condition is:

• Lifelong — the pattern of low desire has been present since the individual became sexually active
• Acquired — the low desire developed after a period of relatively normal sexual interest
• Generalized — not limited to certain types of stimulation, situations, or partners
• Situational — occurs only with certain types of stimulation, situations, or partners

The severity can also be specified as mild, moderate, or severe based on the level of distress it causes.

Prevalence estimates vary depending on how the condition is defined and measured. The DSM-5-TR notes that approximately 6% of younger men (aged 18–24) and 41% of older men (aged 66–74) report problems with sexual desire. However, when applying strict diagnostic criteria that require clinically significant distress, the prevalence of diagnosable MHSDD is considerably lower, with research suggesting rates of approximately 1.8% to 5% of men across various age groups. Despite these numbers, MHSDD is likely underreported due to stigma, cultural expectations around male sexuality, and the common misconception that men always want sex.

The central feature of MHSDD is a marked reduction or absence of interest in sexual activity. However, the presentation can be nuanced, and the symptoms extend beyond simply "not wanting sex." Key indicators include:

• Absent or significantly reduced sexual fantasies and erotic thoughts: The individual rarely or never has spontaneous sexual thoughts, daydreams, or fantasies. This represents a departure from the individual's own baseline or from what would be expected given their age and relationship context.
• Reduced or absent desire to initiate sexual activity: The person consistently avoids initiating sexual encounters and shows little motivation to seek out sexual experiences.
• Reduced receptivity to a partner's sexual advances: When a partner initiates sexual contact, the individual is frequently uninterested, avoidant, or participates only out of obligation rather than genuine desire.
• Diminished interest in sexual cues: Stimuli that would previously have elicited arousal or interest — visual, tactile, situational — no longer produce a notable response.
• Emotional distress related to the lack of desire: The individual experiences feelings of frustration, inadequacy, confusion, shame, or sadness about their low sexual interest. This distress is a required component of the diagnosis.

Warning signs that someone may be experiencing MHSDD rather than a temporary dip in libido include:

• The low desire has persisted for six months or longer
• The pattern is causing significant personal distress or relationship conflict
• The individual has begun avoiding intimacy or physical closeness altogether
• The person feels a marked disconnect between what they believe they "should" feel sexually and what they actually experience
• The decrease in desire is not solely linked to an identifiable stressor that has since resolved

Notably, MHSDD can co-occur with other sexual dysfunctions, such as erectile dysfunction. In some cases, repeated erectile difficulties lead to avoidance and eventually diminished desire, creating a cycle that can be difficult to untangle without professional assessment.

MHSDD is a multifactorial condition, meaning it rarely arises from a single cause. Instead, it typically results from the interplay of biological, psychological, relational, and sociocultural factors. Understanding these contributing elements is critical for effective treatment.

Biological Factors

• Hormonal imbalances: Testosterone is the primary hormone driving sexual desire in men. Low testosterone levels (hypogonadism) — whether due to aging, medical conditions, or other causes — are strongly associated with reduced libido. However, testosterone levels alone do not fully predict sexual desire, and many men with low-normal testosterone maintain healthy libidos.
• Medical conditions: Chronic illnesses such as diabetes, cardiovascular disease, chronic kidney disease, obesity, and neurological disorders can diminish sexual desire through hormonal, vascular, neurological, or fatigue-related mechanisms.
• Medications: Several classes of medication are known to reduce libido, including selective serotonin reuptake inhibitors (SSRIs) and other antidepressants, antipsychotics, opioids, anti-androgens, 5-alpha-reductase inhibitors (used for hair loss and prostate conditions), and some antihypertensives.
• Substance use: Chronic alcohol use, cannabis use, and use of other recreational substances can impair hormonal balance and neurological function, contributing to low desire.
• Age-related changes: While reduced desire is not an inevitable consequence of aging, testosterone levels gradually decline with age (approximately 1–2% per year after age 30), and the prevalence of medical comorbidities increases.

Psychological Factors

• Depression and anxiety: Mood disorders are among the most common psychological contributors to low sexual desire. Depression in particular is characterized by anhedonia — loss of interest or pleasure in activities — which extends to sexuality.
• Performance anxiety: Fear of sexual failure, particularly in men who have experienced erectile difficulties, can lead to avoidance and gradual erosion of desire.
• Body image concerns: Negative perceptions of one's own body can significantly inhibit sexual confidence and desire.
• History of sexual trauma: Past sexual abuse or assault can profoundly affect an individual's relationship with sexuality and desire.
• Stress and burnout: Chronic occupational, financial, or caregiving stress activates the hypothalamic-pituitary-adrenal (HPA) axis, which can suppress the hypothalamic-pituitary-gonadal (HPG) axis responsible for sexual hormone regulation.

Relational Factors

• Relationship dissatisfaction: Ongoing conflict, poor communication, emotional disconnection, or resentment toward a partner can directly suppress sexual desire.
• Desire discrepancy: When partners have significantly different levels of baseline desire, the lower-desire partner may feel pressured, leading to further avoidance and reduced desire.
• Lack of sexual novelty or compatibility: Routine, monotony, or fundamental differences in sexual preferences can erode desire over time.

Sociocultural Factors

• Restrictive cultural or religious beliefs about sexuality can create guilt, shame, or conflict around sexual desire.
• Rigid masculine norms: Paradoxically, the societal expectation that men should always want sex can increase shame and avoidance when desire wanes, preventing men from seeking help.
• Pornography use patterns: Emerging research has explored potential associations between high-frequency pornography use and diminished desire for partnered sex, though this remains an area of active investigation with mixed findings.

Diagnosing MHSDD requires a comprehensive clinical evaluation, as there is no single laboratory test or questionnaire that definitively establishes the diagnosis. The assessment typically involves multiple components:

Clinical Interview

A thorough clinical interview is the cornerstone of diagnosis. A qualified clinician — typically a psychiatrist, psychologist, or sexual medicine specialist — will explore:

• The nature, duration, and onset of the reduced desire
• Whether the pattern is lifelong or acquired, generalized or situational
• The degree of personal distress caused by the low desire
• Sexual history, including past experiences, attitudes, and any history of trauma
• Relationship quality and partner dynamics
• Current mental health status, including screening for depression, anxiety, and other psychiatric conditions
• Medical history and current medications
• Substance use history

DSM-5-TR Diagnostic Criteria

The DSM-5-TR specifies the following criteria for Male Hypoactive Sexual Desire Disorder (302.71 / F52.0):

• Criterion A: Persistently or recurrently deficient (or absent) sexual/erotic thoughts or fantasies and desire for sexual activity. The judgment of deficiency is made by the clinician, taking into account factors that affect sexual functioning, such as age and general and sociocultural contexts of the individual's life.
• Criterion B: The symptoms in Criterion A have persisted for a minimum duration of approximately 6 months.
• Criterion C: The symptoms in Criterion A cause clinically significant distress in the individual.
• Criterion D: The sexual dysfunction is not better explained by a nonsexual mental disorder, significant relationship distress, or other significant stressors and is not attributable to the effects of a substance/medication or another medical condition.

Physical Examination and Laboratory Testing

To rule out underlying medical causes, a physician may conduct:

• A physical examination, including assessment of secondary sexual characteristics and genital examination
• Blood tests to measure total and free testosterone levels, typically drawn in the morning when levels are highest
• Additional hormonal panels including luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, and thyroid function tests
• Metabolic panels, glucose levels, and lipid profiles to assess for underlying metabolic conditions

Validated Questionnaires

Clinicians may also use standardized instruments to quantify desire and distress, such as the Sexual Desire Inventory (SDI), the International Index of Erectile Function (IIEF) (which includes a desire domain), or the Decreased Sexual Desire Screener (DSDS) adapted for males.

A critical part of the diagnostic process is differential diagnosis — distinguishing MHSDD from conditions that can mimic or produce similar symptoms, including major depressive disorder, hypogonadism as a primary endocrine disorder, medication side effects, substance use disorders, and relationship problems that would better account for the reduced desire.

Treatment for MHSDD is guided by the identified contributing factors and is most effective when it addresses the condition's multifactorial nature. A combined approach integrating medical, psychological, and relational interventions tends to produce the best outcomes.

Psychological and Psychotherapeutic Interventions

Cognitive Behavioral Therapy (CBT): CBT for sexual dysfunction targets maladaptive thoughts, beliefs, and behaviors that contribute to low desire. This may include addressing performance anxiety, challenging rigid beliefs about masculinity and sexual performance, and restructuring negative automatic thoughts about sexuality. Research supports CBT's effectiveness in improving sexual desire and reducing sexual distress.

Sex Therapy: Specialized sex therapy, often rooted in the tradition of Masters and Johnson, uses structured behavioral exercises such as sensate focus — a graduated program of non-demand touching designed to reduce performance pressure and rebuild physical intimacy. Sex therapy also addresses sexual communication skills, education about the sexual response cycle, and exploration of erotic preferences.

Mindfulness-Based Interventions: Growing evidence supports the use of mindfulness-based approaches for sexual dysfunction. Mindfulness training helps individuals become more attuned to physical sensations and present-moment experience during sexual encounters, reducing cognitive distraction and spectatoring (mentally monitoring one's own performance during sex).

Couples Therapy: When relational factors play a significant role, couples therapy can address communication breakdowns, resolve conflict, rebuild emotional intimacy, and help partners negotiate desire discrepancies collaboratively.

Psychodynamic Therapy: For individuals whose low desire is rooted in deeper psychological conflicts, attachment difficulties, or past trauma, longer-term psychodynamic or trauma-focused therapy may be appropriate.

Medical and Pharmacological Interventions

Testosterone Replacement Therapy (TRT): For men with clinically documented hypogonadism (low testosterone), testosterone replacement can significantly improve sexual desire. TRT is available in multiple formulations including injections, topical gels, patches, and implantable pellets. However, TRT is appropriate only when low testosterone is confirmed through laboratory testing and is not recommended for men with normal testosterone levels, as supraphysiological testosterone does not reliably increase desire and carries health risks including cardiovascular events, polycythemia, and fertility suppression.

Medication adjustment: If a medication is identified as a likely contributor — particularly SSRIs, which are well-known to impair sexual desire — the prescribing clinician may consider dose reduction, switching to an alternative medication with a more favorable sexual side-effect profile (such as bupropion, mirtazapine, or vilazodone), or adding an adjunctive agent.

Treatment of underlying medical conditions: Optimizing management of diabetes, cardiovascular disease, obesity, thyroid disorders, or hyperprolactinemia can have downstream benefits for sexual desire.

Emerging pharmacological approaches: As of current research, there is no FDA-approved medication specifically for MHSDD (unlike flibanserin for premenopausal women). Some off-label pharmacological approaches that have been studied include bupropion (which has dopaminergic and noradrenergic properties), buspirone, and melanocortin receptor agonists, but evidence remains limited and these are not standard first-line treatments.

Lifestyle Interventions

• Regular physical exercise: Aerobic and resistance exercise have been shown to improve testosterone levels, mood, body image, and overall sexual function.
• Sleep optimization: Poor sleep and sleep disorders such as obstructive sleep apnea are associated with low testosterone and reduced desire.
• Stress management: Practices such as mindfulness meditation, yoga, and structured relaxation techniques can mitigate the impact of chronic stress on the HPG axis.
• Reduction of alcohol and substance use: Moderating or eliminating substances that impair sexual function can yield significant improvements.
• Weight management: Obesity is associated with reduced testosterone, increased estrogen conversion, and impaired sexual function. Weight loss, particularly through a combination of diet and exercise, can improve hormonal profiles and desire.

The prognosis for MHSDD varies considerably depending on the underlying causes, the duration of the condition, the individual's engagement with treatment, and the quality of the therapeutic relationship with providers. However, several general observations can be made based on clinical experience and available research:

Acquired MHSDD generally carries a more favorable prognosis than lifelong MHSDD. When an identifiable and modifiable cause can be found — such as a medication side effect, hypogonadism, or a treatable mood disorder — desire often improves significantly with targeted intervention. Men with acquired MHSDD who previously experienced healthy desire have an established neural and psychological template for sexual interest, which facilitates recovery.

Lifelong MHSDD can be more challenging to treat but is not intractable. Some individuals with lifelong low desire may have biologically lower baseline levels of sexual interest, which may reflect normal variation in sexual desire rather than pathology. For these individuals, therapy may focus more on reducing distress, adjusting expectations, and improving relationship satisfaction rather than dramatically increasing desire frequency.

Multimodal treatment approaches yield the best outcomes. Research consistently shows that addressing biological, psychological, and relational factors simultaneously produces more robust and lasting improvements than addressing any single factor in isolation.

Relationship context matters significantly. Men whose partners are supportive, patient, and willing to engage in couples therapy or sex therapy together tend to experience better outcomes. On the other hand, high-pressure dynamics where the partner demands sexual performance can reinforce avoidance and further suppress desire.

Recovery is often gradual rather than sudden. Patients should be counseled that improvements in desire may take weeks to months, particularly with psychotherapy. Testosterone replacement, when indicated, may begin to improve desire within 3–6 weeks but can take several months to reach full effect.

Importantly, "recovery" does not necessarily mean a return to a prior high level of desire. For many men, particularly those in midlife and beyond, a realistic treatment goal is achieving a level of desire that is satisfying to them and compatible with a fulfilling intimate relationship — which may look different from desire patterns in their twenties.

MHSDD frequently co-occurs with or is related to several other medical and psychological conditions. Understanding these associations helps ensure comprehensive evaluation and treatment:

• Erectile Dysfunction (ED): Perhaps the most common comorbidity. The relationship between MHSDD and ED is often bidirectional — low desire can reduce arousal responses, and repeated erectile failure can lead to avoidance and diminished desire. Distinguishing between primary low desire and low desire secondary to ED is an important diagnostic consideration.
• Major Depressive Disorder: Depression and low sexual desire share significant overlap. Anhedonia, fatigue, and negative self-perception — hallmarks of depression — directly undermine sexual interest. Additionally, many antidepressant medications further suppress desire, creating a complex treatment challenge.
• Generalized Anxiety Disorder and Social Anxiety Disorder: Anxiety, particularly performance anxiety, can inhibit sexual desire and arousal. Chronic worry and hypervigilance are incompatible with the relaxation and present-moment focus required for sexual engagement.
• Hypogonadism: Low testosterone from primary (testicular) or secondary (pituitary/hypothalamic) causes is a medical condition that can directly produce MHSDD symptoms. When hypogonadism is the primary cause, the condition may be better classified as a sexual dysfunction due to another medical condition rather than MHSDD proper.
• Other Sexual Dysfunctions: Delayed ejaculation, premature ejaculation, and genito-pelvic pain can all contribute to diminished sexual desire through frustration, avoidance, and negative associations with sexual activity.
• Relationship Distress: While not a formal psychiatric diagnosis, significant relationship problems are both a cause and consequence of MHSDD. The DSM-5-TR notes that when relationship distress fully accounts for the low desire, a separate diagnosis of MHSDD may not be warranted.
• Substance Use Disorders: Chronic alcohol, opioid, and cannabis use disorders are associated with hormonal disruption and decreased sexual desire.
• Chronic Pain Conditions: Persistent pain conditions can reduce desire through physical discomfort, fatigue, medication effects, and associated depression.
• Obstructive Sleep Apnea: This increasingly recognized condition is associated with reduced testosterone levels, fatigue, and depressed mood — all of which can contribute to low desire.

Because temporary fluctuations in sexual desire are normal, it can be difficult to know when low desire warrants professional evaluation. Consider seeking help if:

• Reduced desire has persisted for six months or longer and does not appear to be resolving on its own
• The low desire is causing you significant personal distress — feelings of frustration, inadequacy, confusion, or loss of identity
• Your relationship is being negatively affected by the desire discrepancy, and attempts to address it between partners have been unsuccessful
• You have noticed other symptoms that might suggest an underlying condition — persistent fatigue, depressed mood, weight gain, reduced muscle mass, difficulty concentrating, or erectile problems
• The onset of low desire coincided with starting a new medication — do not stop prescribed medication without consulting your prescriber, but bring the concern to their attention
• You have a history of trauma that you believe may be affecting your sexual functioning
• You are experiencing thoughts of hopelessness or worthlessness related to your sexual functioning or overall well-being

Where to seek help: An appropriate starting point is often your primary care physician, who can conduct an initial evaluation including hormonal testing and assess for medical causes. From there, referrals may be made to an endocrinologist (for hormonal management), a psychiatrist (for mood disorders or medication management), a psychologist or licensed therapist specializing in sexual dysfunction, or a certified sex therapist (professionals credentialed through organizations such as AASECT — the American Association of Sexuality Educators, Counselors, and Therapists).

Many men delay seeking help for sexual concerns due to embarrassment or the belief that they should be able to resolve the issue on their own. It is worth emphasizing that MHSDD is a recognized clinical condition with well-established treatment approaches, and seeking professional support is a sign of self-awareness and proactive health management, not weakness.

This article is for educational and informational purposes only. It is not a substitute for professional medical or psychological evaluation, diagnosis, or treatment. If you are experiencing symptoms consistent with those described above, please consult a qualified healthcare provider.